Recent advance in targeted therapies for myasthenia gravis / 中华神经医学杂志
Chinese Journal of Neuromedicine
; (12): 310-317, 2024.
Article
en Zh
| WPRIM
| ID: wpr-1035997
Biblioteca responsable:
WPRO
ABSTRACT
Myasthenia gravis (MG) is an autoimmune disease of the nervous system mediated by autoimmune antibodies, dependent on T cells and involved in multiple complement. Recent years, targeted biologics have shown advantages in a number of clinical studies of myasthenia gravis. This review focuses on targeted therapy on B cells, complement, neonatal fragment crystal receptor (FcRn) and cytokine monoclonal antibodies, as well as on the latest research progress of chimeric antigen receptor T cells (CAR-T) or chimeric autoantibody receptor T cells (CAAR-T) in MG therapy, in order to provide the latest drug information for clinicians.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Neuromedicine
Año:
2024
Tipo del documento:
Article